How board members should think about AI

With AI being a buzzword in healthcare, board members of organizations need to know how best to consider the technology. Fortunately, the technology may actually make their job easier, according to Douglas Merrill, who penned an article for Harvard Business Review on what boards should know about AI.

Here are the four guidelines outlined by Merrill, CEO and founder of financial services technology company ZestFinance, for board members to orient themselves as they begin the dive into AI:

Don’t be intimidated. Board members don’t have to have an engineering degree to understand how AI and machine learning can be helpful for their healthcare organization.

Keep it simple. “The best-run AI projects should be explainable in plain English,” Merrill wrote, noting that if a vendor or internal team can’t explain how a program works and what impact it will have, it’s probably not a good fit.

Don’t be creepy. Privacy concerns have taken on new importance in the last few years, but AI projects don’t have to pull every single piece of data about a patient in order to be successful.

Think in operations, not capital investment. A top-down approach to AI should not include a one-time investment. AI has the potential to be part of overall operations instead.

See the full post below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.